Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: * Male or female adults ages 18 to 75 years old when signing the informed consent. * AD (according to Hanifin-Rajka Criteria) that had been present for at least 1 years before the screening visit. * Moderate to Severe Atopic Dermatitis. * Recent history of inadequate response to treatment with topical medications. Exclusion Criteria: * Participation in a prior 611 clinical study. * Treatment with the following prior to the baseline visit: 1) Systemic corticosteroid or Immunosuppressants / Immunomodulators within 4 weeks or within 5 half-lives (if known), whichever is longer. 2) Monoclonal antibody within 5 half-lives (if known) or 4 months, whichever is longer. 3) Cell-depleting within 6 months. * Treatment with a live (attenuated) vaccine within 2 months of the baseline visit or planned during the study. * Serious or Uncontrolled diseases that may affect the safety of participants during the study period or hinder their completion of the study. * Evidence of active acute or chronic hepatitis. * History of malignancy within 5 years before the screening visit or currently. * Pregnant or breastfeeding women, or women planning to become pregnant. * Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).